The FDA has notified healthcare professionals and patients that at this point, the data that have been reviewed have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures.

The FDA, Cangene, and Baxter have notified healthcare professionals that cases of intravascular hemolysis (IVH) and its complications have been reported in patients treated for immune thrombocytopenic purpura (ITP) with WinRho SDF [Rho(D) immune globulin IV (human)].

LifeScan has announced it is conducting a voluntary recall of eight lots of OneTouch SureStep glucose meter test strips because they may provide falsely low glucose results when the glucose level is >400mg/dL.

The FDA has notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart associated with the use of Invirase (saquinavir, from Roche) in combination with Norvir (ritonavir, from Abbott).

The FDA has notified healthcare professionals and patients that it is reviewing the primary clinical trial data from the long-term RECORD study to evaluate the cardiovascular safety of Avandia (rosiglitazone tablets, from GlaxoSmithKline).

The FDA announced that long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma.

The FDA and Novartis have notified healthcare professionals about changes to the Exjade (deferasirox tablets) Prescribing Information, including a Boxed Warning.

The FDA and Novartis Consumer Health have notified healthcare professionals about reports of serious medication errors involving patients who used Maalox Total Relief (bismuth subsalicylate) when they had intended to use a Maalox liquid antacid.

The FDA has approved a risk management program to inform healthcare providers and patients about the risks of erythropoiesis-stimulating agents (ESAs).

The FDA has notified healthcare professionals and patients that the risk of developing progressive multifocal leukoencephalopathy (PML) increases with the number of Tysabri (natalizumab, from Biogen Idec) infusions received.